Need professional-grade analysis? Visit stockanalysis.com
$8.19B
N/A
67
N/A
Abivax SA American Depositary Shares (ABVX) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $120.16, down 1.89% from the previous close.
Over the past year, ABVX has traded between a low of $5.67 and a high of $145.31. The stock has gained 1748.6% over this period. It is currently 17.3% below its 52-week high.
Abivax SA American Depositary Shares has a market capitalization of $8.19B.
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Side-by-side comparison against top Healthcare peers.